AstraZeneca CEO Pascal Soriot (Raphael Lafargue/Abaca/Sipa USA)

A com­bo of As­traZeneca's Imfinzi and chemo wins where oth­ers have failed in piv­otal bil­iary tract test

Look­ing to run with the big dogs in the PD-(L)1 class, As­traZeneca’s Imfinzi has a tall hill to climb to com­pete in an in­creas­ing­ly bustling mar­ket. An ag­gres­sive com­bo strat­e­gy for the drug has paid off so far, and now As­traZeneca is adding an­oth­er notch to its belt.

A com­bo of Imfinzi (dur­val­um­ab) and chemother­a­py sig­nif­i­cant­ly ex­tend­ed the lives of first-line pa­tients with ad­vanced bil­iary tract can­cer over chemo alone, ac­cord­ing to topline re­sults from the Phase III TOPAZ-1 study re­vealed Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.